RU2682270C2 - Рекомбинантный фолликулостимулирующий гормон (ФСГ), включающий альфа-2,3- и альфа-2,6-сиалирование - Google Patents
Рекомбинантный фолликулостимулирующий гормон (ФСГ), включающий альфа-2,3- и альфа-2,6-сиалирование Download PDFInfo
- Publication number
- RU2682270C2 RU2682270C2 RU2014141994A RU2014141994A RU2682270C2 RU 2682270 C2 RU2682270 C2 RU 2682270C2 RU 2014141994 A RU2014141994 A RU 2014141994A RU 2014141994 A RU2014141994 A RU 2014141994A RU 2682270 C2 RU2682270 C2 RU 2682270C2
- Authority
- RU
- Russia
- Prior art keywords
- fsh
- rfsh
- sialylation
- per
- sialyltransferase
- Prior art date
Links
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 title claims abstract description 154
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 title claims abstract description 153
- 229940028334 follicle stimulating hormone Drugs 0.000 title claims abstract description 150
- 102000003838 Sialyltransferases Human genes 0.000 claims abstract description 16
- 108090000141 Sialyltransferases Proteins 0.000 claims abstract description 16
- 230000000694 effects Effects 0.000 claims abstract description 12
- 239000013612 plasmid Substances 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000009450 sialylation Effects 0.000 abstract description 59
- 238000000034 method Methods 0.000 abstract description 26
- 239000000126 substance Substances 0.000 abstract description 21
- 241000282414 Homo sapiens Species 0.000 abstract description 12
- 102000004357 Transferases Human genes 0.000 abstract description 4
- 108090000992 Transferases Proteins 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 63
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 60
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 57
- 238000002360 preparation method Methods 0.000 description 26
- 239000000047 product Substances 0.000 description 21
- 239000000203 mixture Substances 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 19
- 102000001708 Protein Isoforms Human genes 0.000 description 18
- 108010029485 Protein Isoforms Proteins 0.000 description 18
- 125000005629 sialic acid group Chemical group 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 241000700159 Rattus Species 0.000 description 15
- 238000010276 construction Methods 0.000 description 12
- 150000004676 glycans Chemical class 0.000 description 12
- 229940057854 gonal f Drugs 0.000 description 12
- 238000001155 isoelectric focusing Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 210000002700 urine Anatomy 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 10
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 10
- 239000013604 expression vector Substances 0.000 description 9
- 108090000288 Glycoproteins Proteins 0.000 description 8
- 102000003886 Glycoproteins Human genes 0.000 description 8
- 230000002503 metabolic effect Effects 0.000 description 8
- 102000005427 Asialoglycoprotein Receptor Human genes 0.000 description 7
- 102100031974 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Human genes 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 7
- 108010006523 asialoglycoprotein receptor Proteins 0.000 description 7
- 102000035824 beta Subunit Follicle Stimulating Hormone Human genes 0.000 description 7
- 108010081485 beta Subunit Follicle Stimulating Hormone Proteins 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 101000863864 Homo sapiens Beta-galactoside alpha-2,6-sialyltransferase 1 Proteins 0.000 description 6
- 206010058823 Ovarian mass Diseases 0.000 description 6
- 108010000732 alpha Subunit Glycoprotein Hormones Proteins 0.000 description 6
- 108010044715 asialofetuin Proteins 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 210000005260 human cell Anatomy 0.000 description 6
- 102100029945 Beta-galactoside alpha-2,6-sialyltransferase 1 Human genes 0.000 description 5
- 101000703754 Homo sapiens CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Proteins 0.000 description 5
- 102000002287 alpha Subunit Glycoprotein Hormones Human genes 0.000 description 5
- 125000000837 carbohydrate group Chemical group 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000036512 infertility Effects 0.000 description 5
- 208000000509 infertility Diseases 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000004305 normal phase HPLC Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 101710186708 Agglutinin Proteins 0.000 description 4
- 241000699802 Cricetulus griseus Species 0.000 description 4
- 101710146024 Horcolin Proteins 0.000 description 4
- 101710189395 Lectin Proteins 0.000 description 4
- 241001521394 Maackia amurensis Species 0.000 description 4
- 101710179758 Mannose-specific lectin Proteins 0.000 description 4
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 4
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 4
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 4
- 240000006028 Sambucus nigra Species 0.000 description 4
- 235000003142 Sambucus nigra Nutrition 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000000910 agglutinin Substances 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 235000008995 european elder Nutrition 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 231100000535 infertility Toxicity 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000016087 ovulation Effects 0.000 description 4
- 230000001817 pituitary effect Effects 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 101710083574 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Proteins 0.000 description 3
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 108010008699 Mucin-4 Proteins 0.000 description 3
- 102100022693 Mucin-4 Human genes 0.000 description 3
- 102000005348 Neuraminidase Human genes 0.000 description 3
- 108010006232 Neuraminidase Proteins 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 101100539927 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) NAN1 gene Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000005684 electric field Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 230000000624 ovulatory effect Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 2
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical group N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 102000008175 FSH Receptors Human genes 0.000 description 2
- 108010060374 FSH Receptors Proteins 0.000 description 2
- 101150030274 FSHB gene Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102100040796 Glycoprotein hormones alpha chain Human genes 0.000 description 2
- 102000006771 Gonadotropins Human genes 0.000 description 2
- 108010086677 Gonadotropins Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 2
- FDJKUWYYUZCUJX-PGIATKPXSA-N N-glycoloylneuraminic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@@H]1OC(O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-PGIATKPXSA-N 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-L NADH(2-) Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-L 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 108010081934 follitropin beta Proteins 0.000 description 2
- 230000033581 fucosylation Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 210000004368 gonadotroph Anatomy 0.000 description 2
- 239000002622 gonadotropin Substances 0.000 description 2
- 229940094892 gonadotropins Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000009027 insemination Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229940107700 pyruvic acid Drugs 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- JVIPLYCGEZUBIO-UHFFFAOYSA-N 2-(4-fluorophenyl)-1,3-dioxoisoindole-5-carboxylic acid Chemical compound O=C1C2=CC(C(=O)O)=CC=C2C(=O)N1C1=CC=C(F)C=C1 JVIPLYCGEZUBIO-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 229920001425 Diethylaminoethyl cellulose Polymers 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 101000863891 Homo sapiens Beta-galactoside alpha-2,6-sialyltransferase 2 Proteins 0.000 description 1
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 description 1
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 102000048245 N-acetylneuraminate lyases Human genes 0.000 description 1
- 108700023220 N-acetylneuraminate lyases Proteins 0.000 description 1
- SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 description 1
- SUHQNCLNRUAGOO-UHFFFAOYSA-N N-glycoloyl-neuraminic acid Natural products OCC(O)C(O)C(O)C(NC(=O)CO)C(O)CC(=O)C(O)=O SUHQNCLNRUAGOO-UHFFFAOYSA-N 0.000 description 1
- FDJKUWYYUZCUJX-UHFFFAOYSA-N N-glycolyl-beta-neuraminic acid Natural products OCC(O)C(O)C1OC(O)(C(O)=O)CC(O)C1NC(=O)CO FDJKUWYYUZCUJX-UHFFFAOYSA-N 0.000 description 1
- FDJKUWYYUZCUJX-KVNVFURPSA-N N-glycolylneuraminic acid Chemical compound OC[C@H](O)[C@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-KVNVFURPSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 241001524178 Paenarthrobacter ureafaciens Species 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 102000048176 Prostaglandin-D synthases Human genes 0.000 description 1
- 108030003866 Prostaglandin-D synthases Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004198 anterior pituitary gland Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 238000003236 bicinchoninic acid assay Methods 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 238000012850 discrimination method Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 108060002885 fetuin Proteins 0.000 description 1
- 102000013361 fetuin Human genes 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 108010006578 follitropin alfa Proteins 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 150000002302 glucosamines Chemical class 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 102000045442 glycosyltransferase activity proteins Human genes 0.000 description 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 102000048059 human St6Gal2 Human genes 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000006303 immediate early viral mRNA transcription Effects 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 229940060155 neuac Drugs 0.000 description 1
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000008063 pharmaceutical solvent Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000013587 production medium Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 238000013361 sialic acid assay kit Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- -1 without limitation Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
- C12Y204/99006—N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4542408P | 2008-04-16 | 2008-04-16 | |
| US61/045,424 | 2008-04-16 | ||
| EP08251528.9 | 2008-04-25 | ||
| EP08251528 | 2008-04-25 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010141908/10A Division RU2537268C2 (ru) | 2008-04-16 | 2009-04-16 | Рекомбинантный фолликулостимулирующий гормон (фсг), включающий альфа-2, 3- и альфа-2, 6-сиалирование |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018139379A Division RU2745557C3 (ru) | 2008-04-16 | 2018-11-08 | Рекомбинантный фолликулостимулирующий гормон (ФСГ), включающий альфа-2,3- и альфа-2,6-сиалирование |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2014141994A RU2014141994A (ru) | 2016-05-10 |
| RU2014141994A3 RU2014141994A3 (https=) | 2018-05-28 |
| RU2682270C2 true RU2682270C2 (ru) | 2019-03-18 |
Family
ID=39717519
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014141994A RU2682270C2 (ru) | 2008-04-16 | 2009-04-16 | Рекомбинантный фолликулостимулирующий гормон (ФСГ), включающий альфа-2,3- и альфа-2,6-сиалирование |
| RU2010141908/10A RU2537268C2 (ru) | 2008-04-16 | 2009-04-16 | Рекомбинантный фолликулостимулирующий гормон (фсг), включающий альфа-2, 3- и альфа-2, 6-сиалирование |
| RU2018139379A RU2745557C3 (ru) | 2008-04-16 | 2018-11-08 | Рекомбинантный фолликулостимулирующий гормон (ФСГ), включающий альфа-2,3- и альфа-2,6-сиалирование |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010141908/10A RU2537268C2 (ru) | 2008-04-16 | 2009-04-16 | Рекомбинантный фолликулостимулирующий гормон (фсг), включающий альфа-2, 3- и альфа-2, 6-сиалирование |
| RU2018139379A RU2745557C3 (ru) | 2008-04-16 | 2018-11-08 | Рекомбинантный фолликулостимулирующий гормон (ФСГ), включающий альфа-2,3- и альфа-2,6-сиалирование |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US8951967B2 (https=) |
| EP (7) | EP3045471B1 (https=) |
| JP (7) | JP2011519359A (https=) |
| KR (5) | KR20160056960A (https=) |
| CN (3) | CN105906703A (https=) |
| AR (1) | AR071479A1 (https=) |
| AU (5) | AU2009237479B2 (https=) |
| BR (1) | BRPI0910461B8 (https=) |
| CA (1) | CA2725257A1 (https=) |
| CY (1) | CY1115413T1 (https=) |
| DK (6) | DK2808340T3 (https=) |
| ES (5) | ES2468318T3 (https=) |
| FI (4) | FI3098234T3 (https=) |
| FR (3) | FR17C1020I2 (https=) |
| HR (5) | HRP20140535T1 (https=) |
| HU (9) | HUE068565T2 (https=) |
| IL (2) | IL208538A (https=) |
| LT (8) | LT2808340T (https=) |
| MX (3) | MX355457B (https=) |
| NO (4) | NO2017025I1 (https=) |
| NZ (1) | NZ588381A (https=) |
| PL (6) | PL3144318T3 (https=) |
| PT (6) | PT3045471T (https=) |
| RU (3) | RU2682270C2 (https=) |
| SA (1) | SA109300228B1 (https=) |
| SI (6) | SI2268666T1 (https=) |
| TW (1) | TWI488640B (https=) |
| WO (1) | WO2009127826A1 (https=) |
| ZA (1) | ZA201007373B (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI488640B (zh) | 2008-04-16 | 2015-06-21 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
| TWI532495B (zh) | 2009-10-05 | 2016-05-11 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
| EP2417982A1 (en) | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilization of gonadotropins |
| WO2012016576A1 (en) * | 2010-08-04 | 2012-02-09 | Glycotope Gmbh | Improved recombinant human follicle-stimulating hormone |
| PT2621517E (pt) | 2010-09-29 | 2015-10-16 | Ferring Bv | Composição para uso no tratamento da infertilidade |
| WO2012050175A1 (ja) | 2010-10-15 | 2012-04-19 | 日本ケミカルリサーチ株式会社 | 糖鎖の非還元末端がマンノース残基である糖蛋白質の製造方法 |
| PL2691119T3 (pl) | 2011-03-31 | 2019-01-31 | Ferring B.V. | Preparat farmaceutyczny |
| EP2717904A1 (en) | 2011-06-06 | 2014-04-16 | Ferring BV | Pharmaceutical preparation comprising recombinant fsh |
| JO3092B1 (ar) * | 2011-08-08 | 2017-03-15 | Ferring Bv | مركب لتحفيز مسيطر عليه للمبيض |
| WO2013093760A2 (en) * | 2011-12-19 | 2013-06-27 | Grifols, S.A. | Compositions, methods, and kits for preparing sialylated recombinant proteins |
| US9657310B2 (en) * | 2012-04-27 | 2017-05-23 | Jcr Pharmaceuticals Co., Ltd. | Expression vector |
| EP2824176A1 (en) | 2013-07-11 | 2015-01-14 | Siamed'xpress | Methods for producing sialylated therapeutic proteins |
| JP6652334B2 (ja) * | 2014-05-31 | 2020-02-19 | Ｊｃｒファーマ株式会社 | ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地 |
| WO2016102436A1 (en) * | 2014-12-22 | 2016-06-30 | F. Hoffmann-La Roche Ag | Cmp-dependent sialidase activity |
| EP3283097B1 (en) | 2015-04-17 | 2020-02-12 | Ferring B.V. | Fsh for treatment of infertility |
| MY179524A (en) | 2015-06-26 | 2020-11-10 | Ferring Bv | Methods of purification and/or viral inactivation |
| EP3205719A1 (en) * | 2016-02-15 | 2017-08-16 | CEVEC Pharmaceuticals GmbH | Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins |
| GB201603280D0 (en) | 2016-02-24 | 2016-04-13 | Ferring Bv | Stable liquid gonadotropin formulation |
| EP3382014A1 (en) * | 2017-03-29 | 2018-10-03 | CEVEC Pharmaceuticals GmbH | Recombinant glycoproteins with reduced antennary fucosylation |
| EP3441471A1 (en) | 2017-08-08 | 2019-02-13 | CEVEC Pharmaceuticals GmbH | Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines |
| MX2020002235A (es) | 2017-09-01 | 2020-07-20 | Ferring Bv | Composicion para la estimulacion ovarica controlada. |
| HUE071268T2 (hu) | 2018-04-30 | 2025-08-28 | Ferring Bv | Készítmény szabályozott petefészek-stimuláláshoz |
| TWI846743B (zh) | 2018-10-17 | 2024-07-01 | 荷蘭商菲林公司 | 用於控制性卵巢刺激之組成物及方法 |
| US20220380785A1 (en) * | 2019-11-01 | 2022-12-01 | The University Of British Columbia | Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins |
| TW202237173A (zh) | 2020-12-09 | 2022-10-01 | 荷蘭商菲林公司 | 用於受控的卵巢刺激之組成物及方法 |
| KR20240167660A (ko) | 2022-04-01 | 2024-11-27 | 훼링 비.브이. | 불임의 치료를 위한 혼합 프로토콜 |
| AU2023275943A1 (en) | 2022-05-26 | 2024-10-17 | Ferring B.V. | Compositions and methods for treatment of infertility in males |
| KR20250033230A (ko) | 2022-07-08 | 2025-03-07 | 훼링 비.브이. | 자궁내 인공수정(iui)을 위한 조성물 및 방법 |
| AR133300A1 (es) | 2023-07-20 | 2025-09-17 | Ferring Bv | Micropartículas cargadas con fármaco de liberación prolongada |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1206302B (it) | 1987-06-26 | 1989-04-14 | Serono Cesare Ist Ricerca | Ormone follicolo-stimolante urinario |
| US5541083A (en) | 1989-10-24 | 1996-07-30 | The Regents Of The University Of California | Method for producing secretable glycosyltransferases and other golgi processing enzymes |
| IL160406A0 (en) | 1995-06-15 | 2004-07-25 | Crucell Holland Bv | A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products |
| JP3559652B2 (ja) * | 1996-06-25 | 2004-09-02 | グローリー工業株式会社 | 売上精算システムの管理装置 |
| IL122732A0 (en) * | 1997-01-15 | 1998-08-16 | Akzo Nobel Nv | Liquid gonadotropin-containing formulation its preparation and a device containing same |
| JP2001507215A (ja) | 1997-01-16 | 2001-06-05 | サイテル コーポレイション | 組換え糖タンパク質のインビトロでの実用的なシアリル化 |
| JPH1111665A (ja) | 1997-06-28 | 1999-01-19 | Shibuya Kogyo Co Ltd | 無菌エア搬送コンベヤ装置 |
| TWI235158B (en) * | 1997-09-01 | 2005-07-01 | Kirin Brewery | Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same |
| PT1176976E (pt) | 1999-05-07 | 2006-11-30 | Applied Research Systems | Utilização de lh administrada na fase folicular média e tardia para o tratamento de mulheres anovulatórias. |
| JP2002011665A (ja) | 2000-06-28 | 2002-01-15 | Sintokogio Ltd | ショットブラスト装置モニタシステム |
| IL140110A0 (en) | 2000-12-05 | 2002-02-10 | Applied Research Systems | Improvement of homogeneity and secretion of recombinant proteins in mammalian systems |
| MEP38608A (en) * | 2001-10-22 | 2011-02-10 | Merck Serono Sa | Gonadotrophins for folliculogenesis |
| ATE542904T1 (de) | 2001-10-29 | 2012-02-15 | Crucell Holland Bv | Verfahren und mittel zur herstellung von proteinen mit vorbestimmten posttranslationalen modifikationen |
| PT1465987E (pt) | 2001-12-07 | 2008-04-15 | Crucell Holland Bv | Produção de vírus, isolados virais e vacinas |
| US20040248784A1 (en) | 2003-06-03 | 2004-12-09 | Marco Filicori | Unitary combinations of FSH and hCG |
| JP2007515410A (ja) * | 2003-12-03 | 2007-06-14 | ネオス テクノロジーズ インコーポレイテッド | ＧｌｙｃｏＰＥＧ化卵胞刺激ホルモン |
| ES2350298T3 (es) | 2004-02-04 | 2011-01-20 | Centre National De La Recherche Scientifique | Procedimiento para el cribado de anticuerpos específicos de glicoforma. |
| CN103627670B (zh) * | 2004-02-13 | 2016-12-21 | 格莱克托普有限公司 | 高活性糖蛋白加工条件及其有效生产方法 |
| TWI488640B (zh) | 2008-04-16 | 2015-06-21 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
| TWI532495B (zh) | 2009-10-05 | 2016-05-11 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
| EP2417982A1 (en) | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilization of gonadotropins |
| US8790322B2 (en) | 2010-08-03 | 2014-07-29 | King Saud University | Stoma coat |
| WO2012016576A1 (en) * | 2010-08-04 | 2012-02-09 | Glycotope Gmbh | Improved recombinant human follicle-stimulating hormone |
| PT2621517E (pt) | 2010-09-29 | 2015-10-16 | Ferring Bv | Composição para uso no tratamento da infertilidade |
| PL2691119T3 (pl) | 2011-03-31 | 2019-01-31 | Ferring B.V. | Preparat farmaceutyczny |
| EP2717904A1 (en) | 2011-06-06 | 2014-04-16 | Ferring BV | Pharmaceutical preparation comprising recombinant fsh |
| JO3092B1 (ar) | 2011-08-08 | 2017-03-15 | Ferring Bv | مركب لتحفيز مسيطر عليه للمبيض |
| MX2016013449A (es) | 2014-04-18 | 2017-05-04 | Glycotope Gmbh | Hiperestimulacion ovarica controlada con la hormona estimuladora folicular humana recombinante mejorada. |
-
2009
- 2009-04-15 TW TW098112483A patent/TWI488640B/zh active
- 2009-04-16 CN CN201510933827.2A patent/CN105906703A/zh active Pending
- 2009-04-16 HU HUE16179121A patent/HUE068565T2/hu unknown
- 2009-04-16 SI SI200930931T patent/SI2268666T1/sl unknown
- 2009-04-16 CN CN201510933782.9A patent/CN105906702A/zh active Pending
- 2009-04-16 NZ NZ588381A patent/NZ588381A/en unknown
- 2009-04-16 ES ES09733497.3T patent/ES2468318T3/es active Active
- 2009-04-16 FI FIEP16179121.5T patent/FI3098234T3/fi active
- 2009-04-16 SI SI200931670A patent/SI3045471T1/sl unknown
- 2009-04-16 SI SI200932209T patent/SI4015527T1/sl unknown
- 2009-04-16 LT LTEP14178729.1T patent/LT2808340T/lt unknown
- 2009-04-16 MX MX2017007881A patent/MX355457B/es unknown
- 2009-04-16 MX MX2014011348A patent/MX348622B/es unknown
- 2009-04-16 PL PL16194925T patent/PL3144318T3/pl unknown
- 2009-04-16 EP EP16158141.8A patent/EP3045471B1/en not_active Revoked
- 2009-04-16 LT LTEP16179121.5T patent/LT3098234T/lt unknown
- 2009-04-16 AR ARP090101333A patent/AR071479A1/es not_active Application Discontinuation
- 2009-04-16 JP JP2011504527A patent/JP2011519359A/ja active Pending
- 2009-04-16 PT PT161581418T patent/PT3045471T/pt unknown
- 2009-04-16 BR BRPI0910461A patent/BRPI0910461B8/pt active IP Right Grant
- 2009-04-16 ES ES16179121T patent/ES2989729T3/es active Active
- 2009-04-16 EP EP16194925.0A patent/EP3144318B1/en active Active
- 2009-04-16 KR KR1020167012148A patent/KR20160056960A/ko not_active Ceased
- 2009-04-16 FI FIEP21212873.0T patent/FI4015527T3/fi active
- 2009-04-16 MX MX2010011343A patent/MX2010011343A/es active IP Right Grant
- 2009-04-16 HU HUE21212873A patent/HUE071059T2/hu unknown
- 2009-04-16 PT PT97334973T patent/PT2268666E/pt unknown
- 2009-04-16 SI SI200932094T patent/SI3144318T1/sl unknown
- 2009-04-16 PT PT161949250T patent/PT3144318T/pt unknown
- 2009-04-16 WO PCT/GB2009/000978 patent/WO2009127826A1/en not_active Ceased
- 2009-04-16 DK DK14178729.1T patent/DK2808340T3/en active
- 2009-04-16 PL PL09733497T patent/PL2268666T3/pl unknown
- 2009-04-16 EP EP14178729.1A patent/EP2808340B1/en not_active Revoked
- 2009-04-16 SI SI200932205T patent/SI3098234T1/sl unknown
- 2009-04-16 RU RU2014141994A patent/RU2682270C2/ru active
- 2009-04-16 KR KR1020177026920A patent/KR20170110741A/ko not_active Ceased
- 2009-04-16 PL PL21212873.0T patent/PL4015527T3/pl unknown
- 2009-04-16 PT PT141787291T patent/PT2808340T/pt unknown
- 2009-04-16 PL PL16179121.5T patent/PL3098234T3/pl unknown
- 2009-04-16 RU RU2010141908/10A patent/RU2537268C2/ru active
- 2009-04-16 EP EP09733497.3A patent/EP2268666B1/en not_active Revoked
- 2009-04-16 PT PT212128730T patent/PT4015527T/pt unknown
- 2009-04-16 HU HUE16158141A patent/HUE033830T2/en unknown
- 2009-04-16 EP EP13193214.7A patent/EP2722339A1/en active Pending
- 2009-04-16 DK DK16194925.0T patent/DK3144318T3/da active
- 2009-04-16 DK DK09733497.3T patent/DK2268666T3/da active
- 2009-04-16 HU HUE14178729A patent/HUE030652T4/en unknown
- 2009-04-16 SI SI200931547A patent/SI2808340T1/sl unknown
- 2009-04-16 US US12/988,218 patent/US8951967B2/en active Active
- 2009-04-16 HR HRP20140535AT patent/HRP20140535T1/hr unknown
- 2009-04-16 PT PT161791215T patent/PT3098234T/pt unknown
- 2009-04-16 DK DK21212873.0T patent/DK4015527T3/da active
- 2009-04-16 KR KR1020107025581A patent/KR101622944B1/ko active Active
- 2009-04-16 LT LTEP21212873.0T patent/LT4015527T/lt unknown
- 2009-04-16 HR HRP20250313TT patent/HRP20250313T1/hr unknown
- 2009-04-16 ES ES21212873T patent/ES3023526T3/es active Active
- 2009-04-16 HR HRP20241187TT patent/HRP20241187T1/hr unknown
- 2009-04-16 DK DK16158141.8T patent/DK3045471T3/en active
- 2009-04-16 DK DK16179121.5T patent/DK3098234T3/da active
- 2009-04-16 AU AU2009237479A patent/AU2009237479B2/en active Active
- 2009-04-16 CA CA2725257A patent/CA2725257A1/en active Pending
- 2009-04-16 LT LTEP16158141.8T patent/LT3045471T/lt unknown
- 2009-04-16 ES ES16158141.8T patent/ES2629392T3/es active Active
- 2009-04-16 CN CN200980121391XA patent/CN102066414A/zh active Pending
- 2009-04-16 ES ES14178729.1T patent/ES2610277T3/es active Active
- 2009-04-16 KR KR1020197022294A patent/KR102108377B1/ko not_active Expired - Fee Related
- 2009-04-16 KR KR1020187023820A patent/KR20180095140A/ko not_active Ceased
- 2009-04-16 PL PL14178729T patent/PL2808340T3/pl unknown
- 2009-04-16 PL PL16158141T patent/PL3045471T3/pl unknown
- 2009-04-16 EP EP21212873.0A patent/EP4015527B1/en active Active
- 2009-04-16 EP EP16179121.5A patent/EP3098234B1/en active Active
- 2009-04-18 SA SA109300228A patent/SA109300228B1/ar unknown
-
2010
- 2010-10-07 IL IL208538A patent/IL208538A/en active Protection Beyond IP Right Term
- 2010-10-14 ZA ZA2010/07373A patent/ZA201007373B/en unknown
-
2014
- 2014-01-21 IL IL230571A patent/IL230571A/en active IP Right Grant
- 2014-06-06 CY CY20141100402T patent/CY1115413T1/el unknown
- 2014-06-17 AU AU2014203277A patent/AU2014203277C1/en active Active
- 2014-11-14 US US14/541,852 patent/US9546204B2/en active Active
- 2014-12-25 JP JP2014262056A patent/JP2015120696A/ja active Pending
-
2016
- 2016-08-16 US US15/238,362 patent/US9771407B2/en active Active
- 2016-10-07 JP JP2016198588A patent/JP6486310B2/ja active Active
- 2016-11-16 HR HRP20161520TT patent/HRP20161520T1/hr unknown
-
2017
- 2017-05-30 HU HUS1700024C patent/HUS1700024I1/hu unknown
- 2017-05-31 HU HUS1700025C patent/HUS1700025I1/hu unknown
- 2017-06-05 LT LTPA2017018C patent/LTPA2017018I1/lt unknown
- 2017-06-06 FR FR17C1020C patent/FR17C1020I2/fr active Active
- 2017-06-06 NO NO2017025C patent/NO2017025I1/no unknown
- 2017-06-23 AU AU2017204259A patent/AU2017204259B2/en active Active
- 2017-06-23 AU AU2017204258A patent/AU2017204258B2/en active Active
- 2017-06-26 HR HRP20170958TT patent/HRP20170958T1/hr unknown
- 2017-08-01 JP JP2017148823A patent/JP6762916B2/ja active Active
- 2017-08-29 US US15/690,061 patent/US10995128B2/en active Active
- 2017-09-05 AU AU2017225020A patent/AU2017225020B2/en active Active
- 2017-09-27 LT LTPA2017029C patent/LTPA2017029I1/lt unknown
- 2017-09-27 HU HUS1700036C patent/HUS1700036I1/hu unknown
- 2017-09-28 NO NO2017050C patent/NO2017050I1/no unknown
-
2018
- 2018-11-08 RU RU2018139379A patent/RU2745557C3/ru active Protection Beyond IP Right Term
-
2019
- 2019-10-25 JP JP2019194476A patent/JP7316905B2/ja active Active
-
2021
- 2021-04-30 US US17/246,348 patent/US11952407B2/en active Active
- 2021-10-27 JP JP2021175403A patent/JP2022031652A/ja active Pending
-
2023
- 2023-12-21 JP JP2023215339A patent/JP2024038000A/ja active Pending
-
2024
- 2024-03-14 US US18/605,381 patent/US12516094B2/en active Active
-
2025
- 2025-01-15 FI FIC20250003C patent/FIC20250003I1/fi unknown
- 2025-01-16 NO NO2025006C patent/NO2025006I1/no unknown
- 2025-01-16 FR FR25C1003C patent/FR25C1003I1/fr active Active
- 2025-01-24 LT LTPA2025505C patent/LTPA2025505I1/lt unknown
- 2025-01-28 HU HUS2500008C patent/HUS2500008I1/hu unknown
- 2025-07-02 FR FR25C1025C patent/FR25C1025I1/fr active Active
- 2025-07-07 LT LTPA2025525C patent/LTPA2025525I1/lt unknown
- 2025-07-07 HU HUS2500029C patent/HUS2500029I1/hu unknown
- 2025-07-11 FI FIC20250025C patent/FIC20250025I1/fi unknown
- 2025-07-14 NO NO2025032C patent/NO2025032I1/no unknown
Non-Patent Citations (7)
| Title |
|---|
| BOUSFIELD G. R. et al., Comparison of follicle-stimulating hormone glycosylation microheterogenity by quantitative negative mode nano-electrospray mass spectrometry of peptide-N glycanase-released oligosaccharides, Journal of glycomics & lipidomics, 2015, V. 5, N. 1. * |
| FLACK M. R. et al., Increased biological activity due to basic isoforms in recombinant human follicle-stimulating hormone produced in a human cell line, The Journal of Clinical Endocrinology & Metabolism, 1994, V. 79, N. 3, p.756-760. * |
| FLACK M. R. et al., Increased biological activity due to basic isoforms in recombinant human follicle-stimulating hormone produced in a human cell line, The Journal of Clinical Endocrinology & Metabolism, 1994, V. 79, N. 3, p.756-760. BOUSFIELD G. R. et al., Comparison of follicle-stimulating hormone glycosylation microheterogenity by quantitative negative mode nano-electrospray mass spectrometry of peptide-N glycanase-released oligosaccharides, Journal of glycomics & lipidomics, 2015, V. 5, N. 1. ШПАКОВ А. О. ГЛИКОЗИЛИРОВАНИЕ ГОНАДОТРОПИНОВ КАК ВАЖНЕЙШИЙ МЕХАНИЗМ РЕГУЛЯЦИИ ИХ АКТИВНОСТИ, Российский физиологический журнал им. И.М. Сеченова, 2017, т. 103, N. 9, с.1004-1021. ZAMBRANO E. et al., Receptor binding activity and in vitro biological activity of the human FSH charge isoforms as disclosed by heterologous and homologous assay systems, Endocrine, 1999, V. 10, N. 2, p.113-121. KRONMAN C. et al., Hierarchy of Post-translational Modifications Involved in the Circulatory Longevity of * |
| KRONMAN C. et al., Hierarchy of Post-translational Modifications Involved in the Circulatory Longevity of Glycoproteins DEMONSTRATION OF CONCERTED CONTRIBUTIONS OF GLYCAN SIALYLATION AND SUBUNIT ASSEMBLY TO THE PHARMACOKINETIC BEHAVIOR OF BOVINE ACETYLCHOLINESTERASE, Journal of Biological Chemistry, 2000, V. 275, N. 38, p.29488-29502. * |
| ZAMBRANO E. et al., Receptor binding activity and in vitro biological activity of the human FSH charge isoforms as disclosed by heterologous and homologous assay systems, Endocrine, 1999, V. 10, N. 2, p.113-121. * |
| ШИЯН С. Д. и др. СИАЛИЛИРОВАНИЕ N-УГЛЕВОДНЫХ ЦЕПЕЙ ГЛИКОПРОТЕИНОВ С ПОМОЩЬЮ ИММОБИЛИЗОВАННОЙ ТРАНС-СИАЛИДАЗЫ Trypanosoma cruzi, Биоорганическая химия, 2004, т. 30, N. 4, с.400-408. * |
| ШПАКОВ А. О. ГЛИКОЗИЛИРОВАНИЕ ГОНАДОТРОПИНОВ КАК ВАЖНЕЙШИЙ МЕХАНИЗМ РЕГУЛЯЦИИ ИХ АКТИВНОСТИ, Российский физиологический журнал им. И.М. Сеченова, 2017, т. 103, N. 9, с.1004-1021. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2745557C1 (ru) | Рекомбинантный фолликулостимулирующий гормон (ФСГ), включающий альфа-2,3- и альфа-2,6-сиалирование | |
| HK40068781A (en) | Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation | |
| HK40068781B (en) | Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation | |
| ES2833533T3 (es) | FSH recombinante que incluye sialilación alfa 2,3 y alfa 2,6 | |
| HK1227049A1 (en) | Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation | |
| HK1233276A1 (en) | Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation | |
| HK1233276B (en) | Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation | |
| HK1227049B (en) | Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation | |
| HK1197825A (en) | Recombinant fsh including alpha 2,3-and alpha 2,6-sialylation | |
| HK1146284B (en) | Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation | |
| HK1199039B (en) | Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation | |
| HK1227046B (en) | Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation | |
| HK1227046A1 (en) | Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation |